



COMPANY CONTACT:

Endologix, Inc.
Paul McCormick
President and CEO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:

Lippert/Heilshorn & Associates, Inc.
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
(310) 691-7100
www.lhai.com

**WORLD'S FIRST ENDOLOGIX POWERLINK SYSTEM PROCEDURES
PERFORMED WITH VISIFLEX SUREPASS DELIVERY SYSTEM**

IRVINE, Calif. (April 12, 2007) – Endologix, Inc. (Nasdaq: ELGX) today announced the first three successful implantations of the Powerlink® endoluminal stent graft (ELG) incorporating the Visiflex SurePass Delivery System™. The Visiflex SurePass is the Company's next-generation delivery device that allows physicians continued guidewire access to the contralateral limb of the unibody Powerlink ELG device.

The first procedure was completed at William Beaumont Hospital in Royal Oak, Mich., and two additional procedures were completed at the Arizona Heart Hospital in Phoenix, Ariz.

- Venkatesh G. Ramaiah, M.D., Director of Vascular and Endovascular Research at the Arizona Heart Institute, reported, "The SurePass Delivery System further improves upon a delivery technology that is already state-of-the-art in terms of ease of deployment."
- Grayson Wheatley III, M.D., from the Arizona Heart Institute, remarked, "It exceeded my expectations and in this particular case facilitated access to a difficult contralateral limb in a tortuous anatomy."
- O. W. Brown, M.D., from the William Beaumont Hospital, commented, "The technology performed beyond my expectations and I believe the SurePass will further simplify and broaden the applications for Powerlink."

The Visiflex SurePass Delivery System replaces the contralateral limb wire with a hollow guidewire capable of accommodating a standard 0.014 guidewire. The physician can insert the guidewire prior to limb deployment in order to control and maintain access. In patients with complex iliac anatomy physicians often perform adjunctive balloon angioplasty or deliver an extension which requires the use of a guidewire.

"This is a significant improvement to the Powerlink System's design with a focus on upgrading and simplifying the procedure, giving users greater confidence to expand the universe of treatable patients," said Paul McCormick, president and CEO of Endologix. "This is an example of what a company can accomplish with strong clinical collaboration and strength of purpose."

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic

aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

#